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ABSTRACT. A case control study of a defined population from The Netherlands was performed to evaluate 
the risk of femur fractures associated with the use of thiazide diuretics. Included were 386 patients hospital- 
ized for femur fractures between 1986 and 1990 who were residents and 45 years of age and older. Per 
case, one age-, sex-, pharmacy-, and general practitioner-matched control was chosen from the general 
population. Drug use was ascertained from computerized pharmacy records. The adjusted odds ratio of 
current use of thiazide diuretics was 0.5 (95% confidence interval, 0.3-0.9).The protective effect of thiazide 
diuretics was greatest for use of 1 year or longer at relatively high doses of thiizides (odds ratio, 0.3; 95% 
confidence interval, 0.1-0.9). We also found that patients who discontinued thiazide use longer than 2 
months were not protected against femur fractures. These results support the hypothesis that use of thiazide 
diuretics protects against femur fractures. J CLIN EPIDEMIOL 49;l: 115-l 19, 1996. 
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INTRODUCTION 
Femur fractures are a major public health problem among the elderly. 
In The Netherlands, the number of hospitalizations for femur fractures 
has increased two- to threefold since the mid-1970s [l]. By 1990 The 
Netherlands experienced approximately 16,000 admissions for femur 
fractures, estimated to exceed direct costs of 235 million US$ annually 
PI. 
The vast majority of the hip fractures among elderly are typically 
osteoporotic fractures of the proximal femur [3]. With the aging of 
society, the treatment and prevention of bone loss is therefore of the 
utmost importance. However, available drug therapies are either lim- 
ited to women or have been associated with untoward effects [4]. 
During the past decades, experimental studies showed that use of thia- 
zide diuretics slows bone loss, most probably through an increase in 
the renal reabsorption of calcium [5,6]. This slowing of bone loss is 
hypothesized as the principal mechanism responsible for an estimated 
35 to 50% reduction of hip fracture risk among users of thiazide diuret- 
ics 17-91. These findings could be of significant clinical importance 
since thiazide diuretics are relatively inexpensive, well tolerated in low 
dosages by elderly patients, and could be used for treatment of men 
and women in whom use of estrogens is contraindicated [4]. However, 
several studies could not observe a risk reduction among users of thia- 
zide diuretics [lo-121. If use of thiazide diuretics indeed slows bone 
loss, but on the other hand increases the risk for falling by other (e.g., 
postural hypotension) 113) or yet unknown mechanisms, the net effect 
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on hip fracture risk may be disappointing. Because of the controversy 
regarding thiazide-associated hip fracture risk, prescribing and dosing 
differences, and the available assortment of thiazide-containing prepa- 
rations, we performed a case-control study, with adjustment for a wide 
variety of medical risk factors for falling and osteoporosis. 
METHODS 
Setting 
The study used data from the PHARMO record linkage system, a 
database that contains the drug-dispensing records from community 
pharmacies and hospital discharge records of a defined population of 
300,000 residents of 6 medium-sized cities in The Netherlands, of 
whom 52% were females and 30.6% were 45 years of age and older 
[14]. Because almost all patients designate a single pharmacy to fill 
their prescriptions from general practitioners or medical specialists, 
the dispensing histories are virtually complete (151. The computerized 
drug-dispensing histories include data concerning the dispensed drug, 
the prescriber, the dispensing date, the amount dispensed, the pre- 
scribed dose regimens, and the estimated duration of use. For all resi- 
dents, the drug-dispensing histories were linked to patient hospital 
discharge records using a probabilistic algorithm based on patient char- 
acteristics such as date of birth, gender, and general practitioner 
[14,16]. Validation of 9,822 linked records showed that both registers 
are linked with a sensitivity and specificity both exceeding 95%, which 
is comparable to record linkage systems based on unique personal iden- 
tifiers [ 171. The hospital records were obtained from the Dutch Center 
for Health Care Information, a corporation that collates all hospital 
discharge records in The Netherlands into a standardized format. 
These records include detailed information concerning the primary 
and secondary diagnoses, procedures, and dates of admission and dis- 
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All diagnoses are coded according to the Intertmtional 
of Disease, Ninth Revision-Clinical Modification (ICD-9- 
CM). All hospitals use ICD-9-CM E-codes to code for accidental 
injuries. 
charge [18]. 
Classification 
Selection of Case and Control Patients 
Patients, 45 years of age and newly admitted for a femur fracture 
(ICD-9-CM primaty diagnosis code of 820 or 82 1) between January 1, 
1986 through December 21, 1990, were identified from the automated 
hospital records. For each of these case patients, an age- (within 3 
years), sex-, pharmacy-, and general practitioner-matched control was 
randomly selected from the automated drug-dispensing records. An 
index date, the date of femur fracture for case patients, and a corre- 
sponding date for control patients were assigned to each patient. Cases 
and controls had therefore exactly the same length of dispensing and 
hospital admission histories available prior to the index date. Control 
patients had to be alive at the time of hospitalization of a case patient. 
Given an estimated exposure prevalence of thiazides of 18%, we esti- 
mated that approximately 300 patients were needed to detect a relative 
risk of 0.5 ((Y = 0.05 and power = 80%). 
Cases and controls were excluded if they had less than 2 months of 
drug-dispensing history prior to the index date, had evidence of nursing 
home residence or hospital admission as of the index date, or had a 
preventive hip replacement. Of the eligible 386 cases, 357 were admit- 
ted for a fracture of the femoral neck and 29 for fractures of other or 
unspecified parts of the femur. 
Validation 
The primary medical records of 57 cases in 1 of the 6 cities were 
reviewed with respect to the type of the fracture (femur and nonfemur 
fractures) and whether surgical procedures were performed for recon- 
struction of the fracture. All 57 cases represented true femur fractures 
and surgical procedures for reconstruction of the fracture were recorded 
for 54 of these patients (93.1%): 2 patients were mobilized with physio- 
therapy and 1 patient died 1 day after he had been admitted. Valida- 
tion of the femur fractures in other cities was not performed because 
an analysis of the procedure codes recorded in the computerized hospi- 
tal records of all 386 cases also showed that 93.8% of the cases under- 
went a procedure compatible with a reconstruction of the femur frac- 
ture. Therefore, less than 6.2% of all diagnoses of femur fractures may 
have been misclassified, which was also found by others [7]. 
Use of Thi&de Diuretics 
Use of thiazide and other diuretics was ascertained from computerized 
records of prescriptions filled at the community pharmacies for the 
period of 1986 to 1990. For each prescription of a diuretic, the duration 
of each treatment cycle was estimated from the number of dispensed 
tablets divided by the prescribed number of tablets per day. The total 
exposure period per patient was calculated by adding the duration of 
all treatment cycles prior to the index date, corrected for overlap of 
prescriptions. Current users were defined as persons whose index date 
was between the dispensing date of the thiazide and the estimated 
discontinuation date. Long-term users were defined as those who used 
thiazides for more than 1 year. Former users were those not currently 
exposed but who had been prescribed thiazides in the year before the 
index date. To study the effect of discontinuation of thiazides, former 
users were stratified into those who discontinued use within 2 months 
and those who discontinued prior to 2 months of the index date. We 
also calculated the prescribed daily dose of each patient as a fraction 
of the defined daily dose (DDD) [19]. The DDD of a thiazide diuretic 
also equals the standard recommended adult daily dose for treatment 
of hypertension in The Netherlands. 
Assessment of Potential Confounders 
Using information of the automated pharmacy database, we identified 
patients who currently used medications that have been associated 
with an increased risk for accidental injury (benzodiazepines, HI- 
antihistamines, antidepressants, antimigraine preparations, neurolep- 
tics, and opioid analgesics), medication that may influence bone me- 
tabolism (glucocorticoids, aluminum-containing antacids, estrogens, 
vitamin D, calcium, fluor preparations, or etridonates), and other 
drugs of which an increased risk for femur fracture has been reported 
in the literature (nonsteroidal antiinflammatory drugs, laxatives) 
120-221. 
Using information from the hospitalization records, we noted 
whether the case and control patients had a history of hypertension, 
organic brain syndrome, anemia, glaucoma, severe rheumatological 
disease, neoplasms, cerebrovascular disease, peripheral vascular dis- 
ease, cardiac disease (congestive heart failure, myocardial infarc- 
tion, or cardiac arrhythmia), chronic obstructive pulmonary disease, 
asthma, diabetes, incontinence, seizure disorders, Parkinson’s disease, 
and a history of hospitalization for other fractures [22-241. In addition 
to noting the presence of ICD-9-CM codes we also identified drugs 
used to treat these diseases (Appendix) [25]. Total days spent in the 
hospital in the year previous to the index date was also assessed [26]. 
Statistical Analysis 
Conditional logistic regression analyses were performed using EGRET 
[27] to estimate the crude and adjusted odds ratio and 95% confidence 
intervals for femur fracture associated with use of thiazides. Adjusted 
estimates of the odds ratio were controlled for the potential confound- 
ing effects of a history of any hospitalization in the preceding year, a 
history of fractures, organic brain syndrome, mental illness, severe 
rheumatological disorders, cerebrovascular disease, peripheral arterial 
disease, anemia, seizure disorders, incontinence, a history of use of 
drugs used to treat osteoporosis (estrogen, vitamin D, calcium, fluor, 
or etridonates), and current or former use of psychotropic drugs, furose- 
mide, or corticosteroids. These factors were selected because either 
they caused a change in the crude matched odds ratio of at least 10% 
or because of a substantial association of thiazides with hospitalization 
for femur fractures (odds ratio, >1.5 or ~0.67) in our data set [10,28]. 
Subgroup analyses were performed for males and females by applying 
the same final multivariate model used in the total sample. The effects 
of dose, duration, and discontinuation of thiazide use were also studied, 
using the same final multivariate models as used for the total popu- 
lation. 
RESULTS 
The cases and controls had a mean observation period of 2.3 years 
prior to the index date. Of the cases, 69.2% were older than 75 years 
of age and 11.9% were older than 90 years of age (Table 1). Approxi- 
mately 75% of the cases were women. The health status of case pa- 
tients was poorer than that of control patients, as measured by days 
of hospitalization in the year prior to the index date. Medical condi- 
tions found to be more prevalent among case patients than among 
control patients were anemia, severe rheumatological disease, organic 
brain syndrome, cerebrovascular disease, peripheral arterial disease, 
Femur Fracture Prevention and Current Thiazide Use 117 
TABLE 1. Baseline distribution of matching factors, medical 
factors, and exposures 
cases Controls 
Characteristic (n = 386) (n = 386) 
was 0.4 (95% CI, 0.3-0.8) whereas a higher risk was observed for 
patients using both thiazides and benzodiazepines (odds ratio [OR], 
1.2; 95% CI, 0.6-2.3). Controlling for potential confounders lowered 
the odds ratio only slightly from 0.6 (95% CI, 0.4-0.9) to 0.5 (95% 
CI, 0.3-0.9). Although the protective effects was more prominent in 
males than in women, this difference was not statistically significant 
(p = 0.2). The largest confounding effect was observed for concomi- 
tant use of benzodiazepines: 53.2% of cases and 28.1% of controls 
using thiazides also used benzodiazepines concomitantly. 
Mean age ( yr) 
Sex (males) 
Days hospitalized in previous year 
0 days 
l-9 days 
>9 days 
One or more prescriptions as of the index 
date 
Medical condition 
Hypertension 
Cardiac disease 
Incontinence 
Anemia 
COPD and asthma 
Diabetes 
Glaucoma and cataract 
Mental disorders and dementia 
Peripheral and cerebrovascular dis- 
orders 
Parkinson disease 
History of fracture (excluding hip 
fracture) 
Epilepsy 
Severe rheumatological disease 
Current use of medications 
Benzodiazepines 
Nonsteroidal antiinflammatory drugs 
Laxatives 
Furosemide 
H ,-Antihistamines 
Neuroleptics 
Antidepressants 
Former use of medications 
Furosemide 
Estrogen, calcium, fluor, or vitamin D 
Systemic glucocorticoids 
78 
25.1% 
77.5% 
5.2% 
15.3% 
77.0% 
32.9% 
24.9% 
22.5% 
16.1% 
14.8% 
9.1% 
7.3% 
6.4% 
6.0% 
4.9% 
4.7% 
3.4% 
3.4% 
30.0% 
12.4% 
11.1% 
11.1% 
6.7% 
3.1% 
2.8% 
15.6% 
12.4% 
10.9% 
78 
25.1% 
88.1% 
6.2% 
5.7% 
79.4% 
34.2% 
24.6% 
14.2% 
9.6% 
12.4% 
11.7% 
7.5% 
2.6% 
1.0% 
3.6% 
1.8% 
2.3% 
0.3% 
23.3% 
8.5% 
4.1% 
9.1% 
3.9% 
1.8% 
1.8% 
8.8% 
8.8% 
4.7% 
and treatment of osteoporosis. A history of nonfemur fractures was 
also associated with an increased risk for femur fracture. 
Case and control patients did not differ in the use of any one or more 
drugs at the index date. Benzodiazepines were the most commonly used 
drugs among cases and controls and were found to be more prevalent 
among case patients compared to control patients (30.0 and 23.3%, 
respectively). 
Twelve percent of the cases and 18% of controls were current users 
of thiazides as of the index date. Ninety-six patients (12.6%) used a 
thiazide diuretic in combination with either triamterene or amiloride: 
epitizide and triamterene (n = 41), hydrochlorthiazide and triamter- 
ene (n = 26), hydrochlorthiazide and amiloride (n = 29). Monoprep- 
arations of thiazide diuretics used by the study group were chlortalidone 
alone (n = 13), hydrochlorthiazide alone (n = 4), chlorthiazide alone 
(n = l), and cyclopenthiazide alone (n = 1). Other diuretics used 
by the study group were furosemide (n = 78) and spironolactone 
(n = 6). 
The crude odds ratio for femur fracture associated with current use 
of thiazides was 0.6 (95% confidence interval [CI] 0.4-0.9) (Table 2). 
The odds ratio for femur fracture among patients solely using thiazides 
The majority of the cases and controls (70.2% and 62.9%, respec- 
tively) were currently using thiazide at doses equal to 0.5 times the 
standard dose. The odds ratio for femur fracture was lowest for those 
using one or more defined daily doses (OR, 0.4; 95% CI, 0.2-0.8). 
A lower risk for femur fracture was observed among patients who used 
thiazides for longer than 1 year (OR, 0.4%; 95% CI, 0.2-0.8). The 
greatest risk reduction was observed among patients who used one or 
more defined daily doses of thiazides for longer than 1 year (OR, 0.3; 
95% CI, 0.1-0.9). 
The risk of femur fracture was also examined among patients who 
formerly used thiazides. Forty-eight case patients and 51 control pa- 
tients were identified as former users of thiazides. Among patients who 
discontinued use of thiazide diuretics longer than 2 months before the 
index date, we observed no risk reduction for femur fracture (OR, 0.8; 
95% CI, 0.4-1.4) whereas patients who discontinued use of thiazide 
diuretics within 2 months of the index date had an odds ratio of 0.4 
(95% CI, 0.2-0.9). 
TABLE 2. Risk of femur fracture among users of thiazide 
diuretics 
Characteristic 
Crude odds 
lWi0 
(95% CI) 
Adjusted odds 
l%ltioa 
(95% CI) 
Gender 
Male 
Female 
Type 
Pure thiazide 
Combination 
Dosage 
0.1-O. 75 DDD eq. 
>0.75 DDD eq. 
Duration of use 
<l yr 
21 yr 
Duration by dosage 
< 1 yr, 0.1-0.75 DDD eq. 
< 1 yr, >O. 75 DDD eq. 
2 1 yr, 0.1-O. 75 DDD eq. 
21 yr, >0.75 DDD eq. 
Discontinuation before index 
date 
Within 2 months 
Before 2 months 
Overall 
0.3 (0.1-0.9) 
0.7 (0.5-1.2) 
0.4 (0.2-1.0) 
0.7 (0.4-1.1) 
0.7 (0.4-1.1) 
0.5 (0.2-0.9) 
0.8 (0.5-1.5) 
0.5 (0.3-0.8) 
0.9 (0.4-1.7) 
0.8 (0.3-1.2) 
0.6 (0.3-1.1) 
0.3 (0.1-0.9) 
0.6 (0.3-1.3) 
1.1 (0.6-1.8) 
0.6 (0.4-0.9) 
0.2 (0.1-0.7) 
0.6 (0.4-1.0) 
0.3 (0.1-0.9) 
0.6 (0.4-1.0) 
0.6 (0.4-l. 1) 
0.4 (0.2-0.8) 
0.7 (0.2-1.3) 
0.4 (0.2-0.8) 
0.9 (0.4-1.7) 
0.4 (0.1-1.3) 
0.5 (0.2-1.1) 
0.3 (0.1-0.9) 
0.4 (0.2-0.9) 
0.8 (0.4-1.4) 
0.5 (0.3-0.9) 
‘Adjusted for days hospitalized before the index date; histoty of hospitalization 
for nonhip fractures; presence of severe rheumatological disease, anemia, or- 
ganic brain syndrome, cerebrovascular disease, peripheral arterial disease, in- 
continence, and osteoporosis; and current use of benzodiazepines, antidepres- 
sants, Hi-antihistamines, neuroleptics, furosemide (former and current), and 
systemic glucocorticoids. 
Abbreviation: DDD, Defined daily dose. 
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DISCUSSION 
Our findings provide evidence that the use of thiazide diuretics is 
associated with a decreased risk for femur fracture [7-91. This risk 
reduction was dose and duration dependent in that the protective 
effect was greatest among those who used thiazides longer than 1 year 
at doses comparable to 50 mg of hydrochlorothiazide or higher. Among 
patients who discontinued use of thiazides more than 2 months before 
the index date, no risk reduction could be observed, suggesting that 
any risk reduction is short-lived. The latter finding is consistent with 
observations made by Transbol et al., who found that bone density 
returned to baseline levels after 1 month when use of thiazide diuretics 
was discontinued [5]. Because we did not have data on bone mineral 
density and bone mineral turnover is slow, another yet unknown 
mechanism could be responsible for the loss of risk reduction after 
discontinuation of thiazides and interpretation of these results should 
be done carefully. 
The risk reduction was most evident among users of pure thiazide 
diuretics compared to patients using thiazide-containing combination 
pills. This difference is probably explained by the 50% lower content of 
thiazides in combination pills [9]. Our findings support the postulated 
mechanism that thiazides cause an increase in renal calcium reabsorp- 
tion, thereby preventing bone loss and reducing the risk of femur 
fractures [4]. 
use of psychotropic drugs (e.g., benzodiazepines, antidepressants, and 
neuroleptics) were more prevalent among patients with femur frac- 
tures, controlling for these potential risk factors had only a minor 
effect on the risk of hospitalization for femur fractures associated with 
the use of thiazide diuretics (Table 2). However, some of the morbidity 
markers used (e.g., dementia) might not have been specific or sensitive 
enough to control for confounding. Furthermore, we could not control 
for the potential confounding effects of body weight, use of alcohol, 
or functional disabilities. These data were not available or not consis- 
tently recorded in the primary medical records and could not be ob- 
tained for the control patients. However, although others did not 
control for these potential confounding risk factors and found an asso- 
ciation between these and the risk of falling, their presence did not 
explain the increased risk for falling among users of thiazide diuretics 
[9,10,29]. We therefore have no reason to believe that the observed 
decreased risk among users of thiazide diuretics is explained by differ- 
ences in body weight, functional disabilities, use of alcohol, or lack 
of controlling for prevailing diseases using morbidity markers. 
Selection bias of controls is unlikely to explain the observed de- 
creased relative risk. To assure that controls were alive and eligible 
for thiazide use and hospitalization for femur fracture, controls had to 
fill any prescription before and after the index date. Healthy patients 
who never filled a prescription were thereby excluded, potentially re- 
sulting in an overestimation of the prevalence of use of thiazide diuret- 
ics and thus an overestimation of the observed risk reduction. How- 
ever, using age- and gender-specific prevalence estimates of the total 
PHARMO population, we estimated the number of control patients 
who used thiazides as 67 as against 70 observed. 
Our study differed in several aspects from studies addressing thiazide- 
associated femur fracture risk. First, proximal femur neck fractures are 
typical of those suffering from type II osteoporosis [3]. Excluding the 
unspecified femur fractures (ICD-9-CM code 821) did not, however, 
influence the risk estimates. Second, the most prescribed daily dose of 
thiazide diuretics in our study (66%) was comparable to 25 mg of 
hydrochlorthiazide, which was much lower than in studies performed 
in the United States, where doses equal to 50 mg of hydrochlorthiazide 
are most frequently prescribed [9-l 11. High doses of thiazide diuretics 
might increase the risk for volume depletion and thus orthostatic or 
postural hypotension, resulting in an increased risk for femur fractures 
by falling [4]. If such a phenomenon exists, thiazide use might follow 
a “J-shaped” dose-dependent risk relationship for femur fractures: low 
doses are not associated with either mechanism and do not result 
in risk reduction or increase for femur fractures, whereas with in- 
creasing dose the risk for falling caused by postural or orthostatic 
hypotension then could supersede the protection against femur frac- 
tures as a result of slowing bone loss. This effect could be more pro- 
nounced if combination pills of thiazide diuretics and reserpine 
or methyldopa, the two latter drugs associated with an increased 
risk for orthostatic hypotension, are frequently used. These com- 
bination pills are not prescribed in The Netherlands but are quite 
commonly used by subjects studied by Felson et al. [9]. However, more 
studies specifically designed to study this hypothetical dose relationship 
are needed. 
Clinical trials are needed to demonstrate the hypothesized calcium- 
mediated mechanism responsible for slowing bone loss and reduction 
of femur fracture risk among users of thiazides [30]. However, even if 
large randomized clinical trials demonstrate such a mechanism, we 
doubt whether use of thiazide diuretics will become a first line therapy 
for the prevention of femur or hip fractures. Our data suggest that 
long-term use of high doses of thiazides is required to achieve a substan- 
tial protection against femur fractures. Moreover, discontinuation of 
thiazide use might result in a rapid loss of this protection. Discontinua- 
tion can probably not be avoided because, especially among elderly 
with impaired renal function, thiazides lack efficacy in lowering blood 
pressure or treatment of edemas. Furthermore, use of high doses of 
thiazides in the elderly could increase the risk for falling and partially 
undo the risk reduction resulting from slowing bone loss, whereas the 
frequency of serious adverse effects, including sudden death, cannot 
be ignored [31]. 
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Severe rheumatological disorders 
Mental disorders and dementia 
PeripheraYcerebrovascular disorders 
Epilepsy 
History of fractures 
Anemia 
Parkinson’s disease 
Incontinence 
Congestive heart failure or arrhythmia 
Hypertension‘ 
Glaucoma and cataract 
Cancer 
COPD and asthma 
Diabetes mellitus 
710.0, 710.1, 710.4, 714.1, 714.81 specific antirheumatic preparations 
290.0-290.9, 291-319/dihydroergocrine 
443.9, 441.0, 441.9, 785.4, 430-438 
345-345.9lantiepileptics 
800-850 (excluding hip fractures 820-821) 
280-289/antianemic preparations 
332.0-332.9/anti-Parkinsonian drugs 
Oxybutynine, flavoxate, or incontinence pads 
426-427.9, 428-428.9lcardiac therapeutics 
Thiazide diuretics, beta-blocking agents, angiotensine converting enzyme inhibitors, or other anti- 
hypertensive use longer than 180 days 
365.0-365.9, 360.0-379.9/antiglaucoma eyedrops 
140.0-171.9, 174-195.8, 200.0-208.9Iantineoplastic drugs 
Antiasthmatics 
725-729, 250-250.9/antidiabetics 
“ICD-9-CM: Intemcxtional Classificarion of Dueases, Ninth RevisionClinical Modification. 
bUse of drugs or admissions for disease in the year prior to the hip fracture. 
‘In the logistic model these drug groups are included separately. 
Abbreviation: COPD, Chronic obstructive pulmonary disease. 
